ATRIUM THERAPEUTICS INC (RNA) Forecast, Price Target & Analyst Ratings
NASDAQ:RNA • US05370A1088
13.75 USD
-0.79 (-5.43%)
At close: Mar 13, 2026
13.75 USD
0 (0%)
After Hours: 3/13/2026, 5:20:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ATRIUM THERAPEUTICS INC (RNA).
Forecast Snapshot
Consensus Price Target
$74.07
+ 438.67% Upside
Next Earnings Forecast
Release DateMar 3, 2026
PeriodQ4 / 2025
EPS Estimate-$1.27
Revenue Estimate3.385M
ChartMill Buy Consensus
67.78%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$74.07
Upside
+ 438.67%
From current price of $13.75 to mean target of $74.07, Based on 18 analyst forecasts
Low
$65.65
Median
$73.44
High
$100.80
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
18 Wall Street analysts provided a forecast for the next 12 months for RNA. The average price target is 74.07 USD. This implies a price increase of 438.67% is expected in the next year compared to the current price of 13.75.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
67.78%
RNA was analyzed by 18 analysts. The buy percentage consensus is at 68. So analysts seem to be have mildly positive about RNA.
In the previous month the buy percentage consensus was at a similar level.
RNA was analyzed by 18 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | Wells Fargo | Initiate | Overweight |
| 2025-11-11 | Chardan Capital | Maintains | Neutral -> Neutral |
| 2025-10-29 | TD Cowen | Downgrade | Buy -> Hold |
| 2025-10-28 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2025-10-28 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-10-27 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-10-27 | Bernstein | Downgrade | Outperform -> Market Perform |
| 2025-10-27 | Needham | Downgrade | Buy -> Hold |
| 2025-10-27 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2025-10-27 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-10-27 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-09-22 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-09-17 | Roth Capital | Initiate | Buy |
| 2025-09-15 | B of A Securities | Maintains | Buy -> Buy |
| 2025-09-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-10 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-10 | Goldman Sachs | Reiterate | Buy |
| 2025-06-27 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-06-17 | Wolfe Research | Initiate | Outperform |
| 2025-06-11 | Raymond James | Initiate | Strong Buy |
| 2025-06-10 | Barclays | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 3, 2026
PeriodQ4 / 2025
EPS Estimate-$1.27
Revenue Estimate3.385M
Revenue Q2Q13.86%
EPS Q2Q-58.86%
Number of Analysts14
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-11.11%
EPS (1 Month)
0.00%
EPS (3 Months)
0.41%
Next Earnings Summary
RNA is expected to report earnings on 3/3/2026. The consensus EPS estimate for the next earnings is -1.27 USD and the consensus revenue estimate is 3.38M USD.
The next earnings revenue estimate has been revised downward by 11.11% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 9.22M -1.18% | 9.56M 3.69% | 10.897M 13.99% | 20.499M 88.12% | 24.211M 18.11% | 297.04M 1,126.88% | 888.77M 199.21% | 1.439B 61.91% | 2.027B 40.86% | 2.638B 30.14% | 3.097B 17.40% | 3.466B 11.91% | |
| EBITDA YoY % growth | -177.52M -51.20% | -233.497M -31.53% | -376.16M -61.10% | -680.232M -80.84% | -754.623M -10.94% | -590.505M 21.75% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -178.91M -51.55% | -235.598M -31.69% | -378.936M -60.84% | -678.882M -79.15% | -801.666M -18.09% | -617.412M 22.98% | -128.53M 79.18% | 495.22M 485.29% | 928.51M 87.49% | 1.398B 50.56% | 1.744B 24.75% | 2.01B 15.25% | |
| Operating Margin | -1,940.46% | -2,464.41% | -3,477.43% | -3,311.78% | -3,311.17% | -207.85% | -14.46% | 34.41% | 45.81% | 52.99% | 56.31% | 57.99% | |
| EPS YoY % growth | -3.33 -17.25% | -2.90 12.91% | -2.89 0.34% | -4.55 -57.40% | -5.20 -14.21% | -4.38 15.63% | -1.23 71.97% | 4.68 480.54% | 6.90 47.62% | 8.75 26.77% | 9.31 6.41% | 9.46 1.63% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.27 -58.86% | -1.29 -43.22% | -1.32 -9.35% | -1.37 -8.06% | -1.38 -8.43% |
| Revenue Q2Q % growth | 3.385M 13.86% | 2.802M 78.13% | 2.802M -27.16% | 5.412M -56.62% | 11.194M 230.69% |
| EBITDA Q2Q % growth | -186.508M -57.77% | -177.418M -35.71% | -179.545M -5.90% | -208.583M -12.05% | N/A |
| EBIT Q2Q % growth | -197.566M -63.29% | -200.579M -52.51% | -206.708M -20.78% | -216.145M -14.48% | -216.14M -9.40% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-14.90%
EPS Next 5 Year
29.33%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
223.76%
Revenue Next 5 Year
177.45%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-17.56%
EBIT Next 5 Year
N/A
ATRIUM THERAPEUTICS INC / RNA Forecast FAQ
What do analysts expect the price target to be for ATRIUM THERAPEUTICS INC (RNA)?
18 analysts have analysed RNA and the average price target is 74.07 USD. This implies a price increase of 438.67% is expected in the next year compared to the current price of 13.75.
When does ATRIUM THERAPEUTICS INC (RNA) report earnings?
ATRIUM THERAPEUTICS INC (RNA) will report earnings on 2026-03-03, after the market close.
Can you provide the consensus estimates for ATRIUM THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of ATRIUM THERAPEUTICS INC (RNA) is -1.27 USD and the consensus revenue estimate is 3.38M USD.
What is the expected long term growth rate for ATRIUM THERAPEUTICS INC (RNA)?
The expected long term growth rate for ATRIUM THERAPEUTICS INC (RNA) is 223.76%.